Review the latest treatment guidelines available for adults living with immune thrombocytopenia in Australia and New Zealand.

These guidelines were last updated in late 2023 due to a number of factors. These include:

• changes to the Pharmaceutical Benefits Scheme (PBS) reimbursement criteria in Australia and since the original consensus treatment guidelines.¹
• These include:
  • A splenectomy is no longer required to access thrombopoietin receptor agonists (TPO-RAs) such as romplostim and eltrombopag.
  • There are now three TPO-RA available in Australia. These include Romiplostim (NPlate), Eltrombopag (Revolade) and Avatrombopag (Doptelet).
  • Easier to switch between the available TPO-RAs.
  • Rituximab is now unrestricted on the PBS.

Download the updated Consensus Guidelines & update here.

Publish Date: January 1, 2024